Method of producing agent, binding with pre-vasopressin or its fragments

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and method of producing binding agent or mixture of binding agents, capable to bind with epitope, contained in amino acid sequence, corresponding to C-end part of pre-vasopressin, consisting of amino acids 146-163, but not containing amino acid 164, where said method includes steps of producing binding agent with help of forming agent; determination binding ability of binding agent with amino acid sequence with length of at least 12 amino acids, contained in amino acid sequence, corresponding to C-end part, but not containing amino acid 164 of pre-vasopressin; selection of binding agent from multitude of binding agents. Group of inventions also relates to forming agent for producing binding agent or mixture of binding agents; application of binding agent for qualitative or quantitative detection of pre-vasopressin or its fragments in biological sample.

EFFECT: group of inventions provides qualitative or quantitative detection of pre-vasopressin or its fragments in biological sample.

20 cl, 1 ex, 5 dwg, 2 tbl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: blood serum anti-Mullerian hormone (AMH) is measured on the 3-5th day of the menstrual cycle by the immunoenzyme method, and an antral follicle count of 2-5 mm in diameter is derived on the 5-7th day of the menstrual cycle by means of transvaginal ultrasonic examination. The ovulatory menstrual cycles are predicted, if the measured AMH is from 5.0 to 8.0 ng/ml, while the antral follicle count in the ovary makes up to 10.

EFFECT: obtaining reliable results for the purpose of prescribing an adequate treatment in the adolescence and reproductive age aiming at detecting the ovulatory menstrual cycles and preventing endocrine sterility.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: serum hormones are measured on the second day of the menstrual cycle prior to peroral administering letrozole aromatase inhibitor 10 mg and 48 hours after; pre-letrozole oestradiol and anti-Mullerian hormone and post-letrozole oestradiol are measured. An absolute decrease of post-letrozole oestradiol is determined, and an ovarian aromatase activity coefficient (K) is determined by formula. If K <9.1, the low ovarian aromatase activity is determined, the 9.1<K<27.3 shows the normal activity, while K>27.3 - the high activity.

EFFECT: using the declared non-invasive method enables the high-accuracy assessment of the ovarian aromatase activity intensity.

5 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves measuring total blood thyroxin, conducting spinal X-ray osteodensitometry and spirometry, and measuring mineral bone density at the lumbar level of L2-L3, and maximal expiratory flow at 25% and 50% of respiratory function. The obtained data are used to calculate F by formula F=25.1-0.14×a1-15.7×a2+0.42×a3-0.034×a4, wherein 25.1 is a constant; 0.14; 15.7; 0.42; 0.034 are discriminant coefficients; a1, 2,, 4 are numerical values of the conducted examination; a1 is the total thyroxin concentration, nmol/l; a2 is a bone L2-L3 density coefficient; a3 is the maximal expiratory flow at 25% according to respiratory function, %; a4 is the maximal expiratory flow at 50% according to respiratory function, %. If F is equal to or more than the constant, the patient is stated to have no signs of health situations specific for this type of industry; if F is less than the constant, the patient is referred to a risk group of health situations.

EFFECT: method enables detecting the incipient signs of health situations in workers.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to a method for detecting the synchronous tumour growth in the male patients suffering colon cancer. Substance of the invention consists in measuring preoperative blood testosterone and intestinal cell-stimulating hormone by Immunotech test systems (Czech Republic) in the male patients suffering colon cancer. Testosterone/intestinal cell-stimulating hormone ratio is calculated; if the derived value falls within the range of 0.45-2.18 enables stating the presence of single colon cancer, while the values within the range of 0.03-0.38 provides stating the presence of synchronous tumours.

EFFECT: using the declared method enables the more accurate preoperative detection of single or synchronous growth in the given category of patients.

3 ex

FIELD: medicine.

SUBSTANCE: technique involves a blood serum examination for thyrotropic hormone, mcUnit/ml, free T4, pmole/l, prolactine, mIU/ml, follicle-stimulating hormone, mIU/ml, lutenizing hormone, mIU/ml, testosterone, nmole/l, dehydroepiandrosterone sulphate, mcg/ml, cortisol, nmole/l, oestradiol, pg/ml, 17-OH progesterone, nmole/l. Calculating an integral hormone state (HIS) by formula follows. If the HIS value is below 0.799, a habitual disorder is stated, which is accompanied by a minimum risk of the reproductive disorders. The HIS values falling from the range of 0.800 to 1.000 provides stating the tensed hormonal regulation reflecting a moderate risk of the reproductive disorders. The disturbed interhormonal cooperation corresponds to the HIS value falling within the range of 1.001 to ≤1.210 that represents a high risk of the reproductive disorders. The HIS value of more than 1.211 shows the lack of reserves that testifies to a very high risk of the reproductive disorders.

EFFECT: technique enables improving the diagnosis of the adolescent's reproductive disorders.

5 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: for immature girls after day 3-5 of menstrual cycle a level of Anti-Mullerian Hormone is determined in blood serum by method of enzyme multiplied immunoassay (ELISA), and if its value exceeds 5.2 ng/ml the menstrual dysfunction is diagnosed against the background of polycystic ovarian syndrome.

EFFECT: use of specified method increases accuracy of diagnostics and execution of the appropriate remedial measures relating polycystic ovarian syndrome.

6 ex

FIELD: medicine.

SUBSTANCE: method involves detecting a threatening miscarriage and a carrier state of the polymorphism in the gene of folate metabolism, as well as a CD54+ lymphocyte ratio, lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) levels in venous blood of a pregnant woman from the onset of pregnancy to the end of the first trimester. That is followed by calculating a prognostic index (PI) by formula: PI=0.7199X1+1.2552X2-0.00653X3-0.0009X4+0.0722X5+1.1277, wherein X1 is the threatening miscarriage, yes/no (1/0); X2 is the polymorphism in the gene of folate metabolism, yes/no (1/0); X3 is the CD54+ lymphocyte ratio, %; X4 is the lactoferrin level, ng/ml; X5 is the concentration of the free β-subunit of human chorionic gonadotropin (β-HCG), ng/ml. If PI<0, the gestational complications are predicted, while PI>0 enables stating a low risk of pathological conditions accompanying pregnancy. A sensitivity of the presented method makes 81.2%, its specificity is 85.1%. The method effectiveness is 83.2%.

EFFECT: method is minimally invasive, enables identifying a risk group of the gestational complications early that makes it possible to implement preventive measures aiming at preventing the pathological course of the pregnancy.

5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. Substance of the early diagnostic technique for chronic renal disease consists in using a dosage range of dopamine of 1 to 3 mcg/kg of body weight and a standard water load of 200 ml. No glomerular filtration rate increase testifies to the presence of early signs of chronic renal disease.

EFFECT: using the declared technique enables standardising the examination as high as possible by precise dosage measurement of the preparation.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: first stage comprises a night suppressive test with dexamethasone 1 mg with a test considered to be positive, if plasma cortisol measured at 8.00 in the next morning exceeds 50 nmole/l. If the first stage has a positive result, the second stage is performed 1-2 days later. At the second stage, blood plasma cortisol at 24.00, daily urine free cortisol, a coefficient of circadian rhythm of cortisol secretion are determined on the same day. If at least two of the three test results are above normal: plasma cortisol at 24.00 is more than 207 nmole/l, daily urine free cortisol is more than 180 mcg/day, coefficient of circadian rhythm of cortisol secretion is more than 50%, hypercorticoidism syndrome is diagnosed. The presented technique provides higher accuracy and simplifies diagnosing of the given disease.

EFFECT: technique enables well-timed adequate therapeutic approach, prevents the disease transformation into manifestative hypercorticoidism with developing severe disabling complications.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of immunology, namely to enzyme-immunoassay, in particular to a method of detecting forms of vascular endothelial growth factor (VEGF) with a size more than 110 amino acids in a biological sample. The method includes the following stages: contact and incubation of the biological sample with an uptake reagent, immobilised on a solid substrate, where the uptake reagent contains a monoclonal antibody, which recognises and specifically binds with residues, in quantity more than 110, from human VEGF; separation of the biological sample from the immobilised uptake reagents; contact of the immobilised molecular complex of the reagent of the uptake-target with detected antibody, which binds with VEGF domains, responsible for binding with KDR and/or FLT1 receptor, or which binds with an epitope in VEGF1-110; measurement of the level of VEGF110+, bound with reagents of the uptake, with application of means of detection for the detected antibody. Set of immune assay reagents for detection of VEGF110+ forms in the biological sample. An antibody 5C3, obtained from hybridoma 5C3.1.1 with a depositary number PTA-7737, with the said antibody 5C3 binding VEGF110+ forms, including VEGF121+. Hybridoma 5C3.1.1, deposited in ATCC with the depositary number PTA-7737, to obtain the monoclonal antibody 5C3.

EFFECT: application of the claimed invention makes it possible to increase accuracy of detecting VEGF isoforms, which must not include isoform VEGF110 and must obligatory include isoform VEGF121.

25 cl, 3 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is presented is a method for the prediction of the postpartum osteopenic syndrome involving studying VDR gene polymorphism Fok-I and predicting the osteopenic syndrome having the genotypes Ff or ff detected. If the genotype FF of the VDR gene polymorphism Fok-I is detected, the VDR gene polymorphism ApaI, BsmI and TaqI are studied additionally. If having at least one of the VDR genotypes AA, Aa ApaI, BB, Bb BsmI and Tt, tt TaqI detected, the postpartum osteopenic syndrome is predicted to develop.

EFFECT: presented method enables predicting the developing postpartum osteopenic syndrome even before the onset of pregnancy, or at any gestational age.

10 ex

FIELD: medicine.

SUBSTANCE: DNA is recovered from peripheral venous blood which is followed by a genetic typing of the APOE gene and detecting polymorphous alleles APOE*2, APOE*3, APOE*4; if the assays shows any genetic types containing alleles APOE*2, a high risk of endometrial cancer is predicted.

EFFECT: invention provides a highly specific criterion for predicting the risk of hyperproliferative diseases of the endometrium, including endometrioid adenocarcinoma in females with hyperplastic processes in the endometrium.

2 dwg, 10 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of diagnosing bipolar affective disorder. The essence of the method consists in the fact that reliable differences in the spectrum of protein distribution in blood serum without proteins albumin, immunoglobulin G, immunoglobulin A, antitrypsin, transferin and haploglobin in patients with endogenic psychosis. If protein spots are detected on electrophoretic gel in areas with the molecular weight of 200, 84, 75, 49, 40 kDa in the patient with endogenic psychosis, bipolar affective disorder is diagnosed.

EFFECT: application of the claimed method makes it possible to increase accuracy in diagnostics being simple in realisation.

2 ex

FIELD: medicine.

SUBSTANCE: method involves determining female serum cytotoxicity to male lymphocytes, including a combined culture with reference male and analysed female serum in a 96-well tray in the presence of the nutrient medium RPMI 1640 in a CO2 incubator. One day later, lymphocytes are counted in the well in a Goryaev's chamber with the male (reference) and female (analysed) serum. That is followed by determining a cytotoxic index (CI), which represents a quotient of the analysed cell count and the reference cell count. The normal cytotoxic index makes approximately 0.7 and less.

EFFECT: invention enables studying the responses of female humoral immune factors to male antigens and evaluating a risk of miscarriage, early spontaneous abortions and missed miscarriages.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine and is intended for the diagnostics of an occlusive affection of vessels in patients with cardiovascular diseases. The age, the level of total homocysteine in blood, the presence of C677T polymorphism mutations in the gene of methyletetrahydrofolate reductase, factor V gene G1691A Leiden mutation, 675 4G/5G polymorphism mutations in the gene of the plasminogen activator inhibitor type I are determined in the patient, after which a value of the discriminant function is calculated by formula. In case of D>0, the presence of the occlusive affection of vessels is diagnosed, if D<0, the absence is diagnosed.

EFFECT: invention provides the effective method for the diagnostics of the occlusive affection of vessels in the patients with cardiovascular diseases.

3 ex

FIELD: medicine.

SUBSTANCE: method includes the determination of an inhibiting impact of a solution of highly-toxic anticholinesterase poison on cholinesterase activity, represented by acetylcholinesterase of human blood erythrocytes, in the presence and in the absence of a substrate, represented by acetylthiocholiniodide. The inhibiting impact of the solution of highly-toxic anticholinesterase poison on the activity of acetylcholinesterase of the human blood erythrocytes is determined first in the presence of the substrate, and then in its absence. An analysed sample is preliminarily diluted by 10 or 100 times to obtain the inhibiting effect on acetylcholinesterase of the human blood erythrocytes in the presence and in the absence of the substrate within 25-75%. After that, the value of the protective effect of acetylthiocholiniodide and the obtained calculated value is compared with table values, determined experimentally in advance for each particular highly-toxic anticholinesterase poison. If the calculated values coincide with the table values, a conclusion about the presence of a respective highly-toxic anticholinesterase poison in the analysed sample is made.

EFFECT: increase of safety.

2 ex

FIELD: medicine.

SUBSTANCE: technique is implemented by biochemical blood analysis followed by determining a diagnostic index by formula: D=X1×K1+X2×K2+X3×K3+X4×K4+const, wherein the values X are described by the biological parameters: X1 is the ceruloplasmin concentration, g/l; X2 is the creatinine concentration, mcmole/l; X3 is the total protein concentration, g/l; X4 is the albumin concentration, g/l; K1, K2, K3; K4 are coefficients: K1=10.4, K2=-0.04, K3=-0.10, K4=0.26, const=-6.84. If D is more than 0, the uncomplicated gestation course is stated with certainty. If D is less than 0, the threatening miscarriage is predicted.

EFFECT: method enables the timely detection of a group of the threatening miscarriage risk, and enables the correct classification.

3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relate to medicine and deals with method of diagnosing neurodegenerative disease in individual, including the following stages (i) determination of one or several parameters, selected from group, consisting of 3ab40 or value of calculated parameter, selected from group, consisting of 2ab40+3ab40, 2ab40+3ab40+2ab42+3ab42 and 1ab40+2ab40+1ab42+2ab42; (ii) comparison of parameter value with standard value, corresponding to value of said parameter in standard sample; and (iii) diagnostics of neurodegenerative disease, in case if increase of parameter value in comparison with standard value is observed. Group of inventions also deals with method of detecting stage, preceding neurodegenerative disease, method of differentiating neurodegenerative disease from stage, preceding said neurodegenerative disease.

EFFECT: group of inventions provide high sensitivity and specificity of detection methods.

13 cl, 12 ex, 14 dwg, 12 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to a method for the prediction of acquired myopia in school children. The substance of the method consists in measuring blood haemoglobin concentrations in 6-8-year-old school children to detect haemoglobin deficiency as shown by the difference of an optimum haemoglobin concentration specific for the above age and an actual haemoglobin concentration in a child. If observing no haemoglobin deficiency at the age of 6-8 years old, a low risk of acquired myopia is predicted. The haemoglobin deficiency to 1.7 g/l enables predicting a risk of acquired low myopia. If the haemoglobin deficiency is 1.7 g/l and more, a high risk of progressive myopia to be developed into moderate or high myopia is predicted.

EFFECT: using the declared method enables developing the reliable and accessible method for the prediction of myopia in the 6-8-year-old children.

2 tbl, 1 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to method of diagnosing rheumatoid arthritis, method of determining therapeutic agent for treatment of rheumatoid arthritis and set for realisation of methods. Methods are characterised by the fact that include stage of measuring amount of talin in plasma or serum of animal subject. Said measurement is carried out, for instance, by immunologic method with application of antibody, binding with talin. If amount of talin is higher than its average value in control subject without rheumatoid arthritis, rheumatoid arthritis is diagnosed in subject. In case of reduction of talin amount after introduction of therapeutic agent in comparison with amount of talin before introduction, therapeutic effect is stated. Set in accordance with claimed invention contains solid-phase carrier, to which antibody, binding with talin, is attached.

EFFECT: increased efficiency of diagnostics.

9 cl, 4 tbl, 4 ex, 3 dwg

FIELD: medicine, ophthalmology.

SUBSTANCE: in lacrimal liquid one should detect the content of interleukin 8 (IL-8) and that of interleukin 1 beta (IL-1β) to calculate prognostic coefficient (PC) due to dividing the first value by the second one by the following formula: At PC value being below 10.0 one should predict favorable disease flow, and at PC value being above 10.0 - unfavorable flow.

EFFECT: higher accuracy of prediction.

2 ex

Up!